Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales

Eli Lilly's growth drivers are expanding beyond its successful GLP-1 drugs, Mounjaro and Zepbound, with new approvals like Omvoh, Ebglyss, Kisunla, and Jaypirca collectively contributing over $540 million in H1 2025. These drugs are undergoing studies for additional indications and geographies, while new therapies like imlunestrant are also awaiting approval. Despite competitive pressures in various therapeutic areas and a year-to-date stock decline of 4.6% (vs. industry +1.3%), analyst consensus EPS estimates for 2025 and 2026 have recently increased, signaling confidence in the expanded pipeline's future contributions, though the stock's 25.87x forward P/E remains elevated compared to the industry average.

Analysis

Eli Lilly is demonstrating a strategic expansion of its revenue base beyond the highly successful GLP-1 drugs, Mounjaro and Zepbound. A portfolio of newly approved therapies, including Omvoh, Ebglyss, Kisunla, and Jaypirca, collectively contributed over $540 million in revenue in the first half of 2025, signaling the early success of this diversification. Future growth is underpinned by potential label expansions for these drugs into new indications and the anticipated approval of imlunestrant for breast cancer. However, this growth narrative is balanced by significant competitive pressures; each new drug faces established incumbents from major pharmaceutical players like AbbVie, J&J, and Sanofi. Despite the stock's year-to-date decline of 4.6% against the industry's 1.3% gain, analyst sentiment remains strong, reflected in the recent upward revisions of the Zacks Consensus EPS Estimates to $22.97 for 2025 and $30.95 for 2026. The stock's valuation remains a key consideration, with a forward P/E ratio of 25.87, substantially higher than the industry average of 14.78, though it is trading below its own 5-year mean.

Key Decisions for Investors

• Investors should evaluate whether the strong growth prospects from the diversifying drug pipeline, supported by rising consensus EPS estimates, justify the stock's premium valuation relative to the sector.
• The recent share price underperformance of -4.6% YTD could be viewed as a potential buying opportunity for those confident in the long-term execution of the non-GLP-1 pipeline.
• Closely monitor the commercial uptake of Omvoh, Jaypirca, and Ebglyss against their formidable competitors, as their market share gains are crucial for validating the company's growth-diversification strategy.
• Key catalysts to watch include regulatory decisions for imlunestrant and clinical trial results for label expansions, which could materially affect future revenue projections and investor sentiment.